Our Vision & Mission
Restoring Health Through Innovation
Vision
iMetabolic Biopharma Corporation is focused on developing safe & effective First In Class therapeutics in the battle against rare, metabolic and cardiometabolic diseases. Motivated to provide patient success, iMBP management and researchers drive innovation for products that ensure efficacy, safety and affordability.
Mission
Through strategic planning and precise execution, iMetabolic Biopharma Corporation has established it’s self as a virtual precision medicine biopharma company. By gaining access to world leading research facilities and their experts, a cost effective and efficient approach to the iMetabolic Biopharma DDD process has been established.
Our Team
Management and Board
Dr. Urban A. Kiernan - Founder, CEO and Board Chairman. With over 20 years of industry business and research experience, Dr. Kiernan is the lead architect in the development of what has now become iMBP. Prior to focusing on iMBP, he was the Director of Biomarker Discovery at Intrinsic Bioprobes Incorporated and later established himself in Global Business Development at Thermo Fisher Scientific.
Dr. Stephen A. Munk - Interim - COO and Board Director. Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts.
Mr. David F. Hendren - Chief Business Officer. Mr. Hendren has 25+ years of experience in building, funding and launching healthcare, life sciences and bio-medically related companies. He has participated in companies that were able to execute IPO, M&A and licensing exit strategies that have a cumulative total that exceeds over $1 Billion.
Mr. Jeffrey D. Zimmerman, Esq. - General Counsel & Board Secretary. Mr. Zimmerman has over three decades of business law expertise. His experience ranges from direct business advisement through complex merger and acquisitions. He also has extensive experience through his participation on the Boards of several not for profit organizations.
Business Advisory Board
Mr. André Harrell - CEO; AH2 & Beyond Consulting. With an industrial life science career that spans three decades, Mr. Harrell has worked with many notable Fortune 100 companies such as Johnson & Johnson Inc, Hewlett Packard, BASF, SC Johnson, Bristol Myers Squibb, Mylan Pharmaceutical, Revlon Professional, Twitter, and Novo Nordisk. Through his efforts he has amassed extensive experience in global commercial strategies and corporate development.
Dr. Martin Emanuele - Co-Founder & COO; Visgenx. With over 30 years of bio-pharmaceutical industry experience; including over two decades in senior executive roles in companies that include CytRx Corp., Avanir Pharmaceuticals and Mast Therapeutics, Dr. Emanuale has experience in developing both research and business teams that have resulted in multiple IND and NDA approvals.
Scientific Advisory Board
Dr. Gerald I. Shulman - Research Professor. Howard Hughes Medical Institute, Yale University School of Medicine
Dr. Michael R. Briggs - President. Woodland Pharmaceuticals, LLC
Dr. Randall W. Nelson - Research Professor (Retired). Molecular Biosignatures Analysis Unit, Biodesign, ASU
Dr. Kirkwood A. Pritchard Jr. - Tenured Professor. Medical College of Wisconsin
Dr. Ira J. Goldberg - Division Director. New York University School of Medicine
Medical Advisory Board
Dr. Kitt Falk Petersen - Endocrinologist. Yale University School of Medicine
Dr. Damon Dixon - Cardiologist & Lipidologist. Phoenix Children's Hospital
Dr. H. Randall Craig - Endocrinologist (Fertility Specialist). Fertility Treatment Center